Log in
Enquire now
‌

US Patent 8722618 IL4/IL13 binding repeat proteins and uses

Patent 8722618 was granted and assigned to Janssen Biotech on May, 2014 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Janssen Biotech
Janssen Biotech
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
87226180
Patent Inventor Names
Michael Baumann0
Gaby Sennhauser0
Karyn O'Neil0
Steven Jacobs0
Date of Patent
May 13, 2014
0
Patent Application Number
134585780
Date Filed
April 27, 2012
0
Patent Citations Received
‌
US Patent 11834504 DARPin based multi-specific t-cell engagers
0
‌
US Patent 11970526 IL4/IL13 receptor molecule for veterinary use
0
Patent Primary Examiner
‌
Karlheinz R. Skowronek
0
Patent abstract

IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpaha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8722618 IL4/IL13 binding repeat proteins and uses

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.